Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Comment by dogwagon Apr 10, 2013 9:24pm

193 Views

Post# 21239660

RE: RE: RE: RE: RE: Hard to digest!!

Hey DF,if you check the winter 2013 presentation,BRD owes 80 million in debentures and 50 million in revenue streams as they pay on 8% as they purchased 4% back for 24 million dollars.130 million minus 30 million in cash leaves 100 million in total debt.LSG owes 230 million minus 80 million in cash which leaves them about 150 million in net debt.These are the figures I come up with from the financials for both companies but SAS looks good also with less resrves mind you.Good chat!!

Bullboard Posts

Sony’s Alpha 1 II: A new professional photography standard?